The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog
Seagen’s Adcetris was trounced by Bristol-Myers Squibb’s Opdivo in a head-to-head trial in classical Hodgkin lymphoma (cHL) reported at ASCO – but there may be a way for t
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
In amongst the big clinical trial readouts at ASCO, a new research project made its official debut with the ambitious goal of mapping cancer cells’ interactions with their
AstraZeneca and Daiichi Sankyo’s Enhertu is already gathering momentum as a treatment for HER2-positive and HER2-low breast, gastric, and lung cancer, but new data could b
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.